Biora Therapeutics, Inc. announced progress with its latest clinical device performance study, evaluating the device function and safety of its NaviCap targeted oral delivery platform. The NaviCap platform uses an ingestible device designed for targeted delivery of therapeutics to improve treatment of IBD. Once swallowed, Biora's GItrac autolocation technology enables the device to autonomously identify targeted locations in the GI tract and release its payload.

Biora?s BT-603 clinical device performance study was designed to evaluate the safety and tolerability of its phase 1-ready NaviCap device and the device?s localization and delivery function in healthy volunteers. During the study, NaviCap devices filled with a saline solution that included radioisotopes were ingested orally by healthy volunteers. Scintigraphic imaging was used to indicate device localization and payload delivery to the lower GI tract.

No drug was administered as part of this study.